JP2023513536A5 - - Google Patents
Info
- Publication number
- JP2023513536A5 JP2023513536A5 JP2022548166A JP2022548166A JP2023513536A5 JP 2023513536 A5 JP2023513536 A5 JP 2023513536A5 JP 2022548166 A JP2022548166 A JP 2022548166A JP 2022548166 A JP2022548166 A JP 2022548166A JP 2023513536 A5 JP2023513536 A5 JP 2023513536A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- myc gene
- myc
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/074515 WO2021155580A1 (en) | 2020-02-07 | 2020-02-07 | Combination therapies and biomarkers for treating cancer |
| CNPCT/CN2020/074515 | 2020-02-07 | ||
| PCT/US2021/016861 WO2021158947A1 (en) | 2020-02-07 | 2021-02-05 | Combination therapies and biomarkers for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513536A JP2023513536A (ja) | 2023-03-31 |
| JP2023513536A5 true JP2023513536A5 (enExample) | 2024-02-29 |
Family
ID=77199733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548166A Pending JP2023513536A (ja) | 2020-02-07 | 2021-02-05 | がんを治療するための併用療法およびバイオマーカー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230104800A1 (enExample) |
| EP (1) | EP4100061A4 (enExample) |
| JP (1) | JP2023513536A (enExample) |
| CN (1) | CN115605227A (enExample) |
| WO (2) | WO2021155580A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CA3109605A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| WO2021155581A1 (en) * | 2020-02-07 | 2021-08-12 | Cothera Bioscience, Inc. | Combination therapies and biomarkers for treating b-cell lymphomas |
| WO2023039803A1 (en) * | 2021-09-16 | 2023-03-23 | Xiang Li | Androgen receptor biomarkers for cancer therapy |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024152052A1 (en) * | 2023-01-13 | 2024-07-18 | Areva Pharmaceuticals Inc. | Compositions comprising fludarabine phosphate and methods of making and using same to treat cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976790A (en) * | 1992-03-04 | 1999-11-02 | The Regents Of The University Of California | Comparative Genomic Hybridization (CGH) |
| US7618992B2 (en) * | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| US8710068B2 (en) * | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| CA2808417A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| JP2014156400A (ja) * | 2011-05-24 | 2014-08-28 | Astellas Pharma Inc | 腫瘍の画像診断用標識誘導体 |
| US20140228423A1 (en) * | 2011-06-01 | 2014-08-14 | Baylor College Of Medicine | Biomarkers and therapy for cancer |
| WO2017079746A2 (en) * | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2017165732A1 (en) * | 2016-03-24 | 2017-09-28 | Tragara Pharmaceuticals, Inc. | Treatment of cancer with tg02 |
| CN106822905B (zh) * | 2017-03-08 | 2019-05-17 | 暨南大学 | 含Survivin抑制剂和IRE1抑制剂的药物及用途 |
| JP2021028297A (ja) * | 2017-11-29 | 2021-02-25 | 国立大学法人 東京医科歯科大学 | マイクロｒｎａ及びその誘導体を有効成分とするがん治療剤 |
| WO2020034061A1 (en) * | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co., Ltd. | Biomarkers for cancer therapy |
| CA3109605A1 (en) * | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| WO2021155581A1 (en) * | 2020-02-07 | 2021-08-12 | Cothera Bioscience, Inc. | Combination therapies and biomarkers for treating b-cell lymphomas |
-
2020
- 2020-02-07 WO PCT/CN2020/074515 patent/WO2021155580A1/en not_active Ceased
-
2021
- 2021-02-05 CN CN202180019819.0A patent/CN115605227A/zh active Pending
- 2021-02-05 JP JP2022548166A patent/JP2023513536A/ja active Pending
- 2021-02-05 WO PCT/US2021/016861 patent/WO2021158947A1/en not_active Ceased
- 2021-02-05 EP EP21750128.7A patent/EP4100061A4/en active Pending
- 2021-02-05 US US17/797,609 patent/US20230104800A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513536A5 (enExample) | ||
| Klebanoff et al. | Prospects for gene-engineered T cell immunotherapy for solid cancers | |
| RU2745707C2 (ru) | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака | |
| JP6607850B2 (ja) | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 | |
| KR20190137151A (ko) | 병용 요법 | |
| JP2020517640A5 (enExample) | ||
| KR20190053909A (ko) | 항체와 체크포인트 면역 억제제의 병용 요법 | |
| AU2014337135A1 (en) | Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody | |
| WO2019114762A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| JP7809635B2 (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| JP2020517629A5 (enExample) | ||
| JP2026021459A (ja) | 黒色腫の処置のためのｌａｇ－３アンタゴニスト | |
| EP3932427A1 (en) | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab | |
| CN113474048A (zh) | 用于癌症治疗的组合物和方法 | |
| WO2019114751A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| KR20230093282A (ko) | 폐암에 대한 lag-3 길항제 요법 | |
| AU2023226078A1 (en) | Combination therapy for colorectal carcinoma. | |
| US11813279B2 (en) | Compositions for cancer therapy and methods | |
| WO2025145207A1 (en) | Combination therapy of kras inhibitor and treg-depleting agent | |
| US20250144138A1 (en) | Chimeric Antigen Receptor Therapies and Vasoactive Intestinal Peptide Receptor Antagonists | |
| KR20250123912A (ko) | 폐암에 대한 병용 요법 | |
| US20230323470A1 (en) | Methods of treating cancer by administering a pd-1 inhibitor | |
| RU2842292C1 (ru) | Способы лечения рака посредством введения ингибитора pd-1 | |
| Albrecht | Assessment of chimeric antigen receptors containing non-canonical signaling domains: Comparative evaluation in different immune cells | |
| HK40050404A (en) | Compositions and methods for cancer therapy |